Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Shield Therapeutics Plc (STX.LN)

Shield Therapeutics Plc (STX.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Shield Therapeutics Plc Northern Design Centre Baltic Business Quarter Newcastle NE8 3DF GBR

https://www.shieldtherapeutics.com P: 191-511-8500

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.

Key Statistics

Overview:

Market Capitalization, $K 91,848
Shares Outstanding, K 1,067,997
% of Insider Shareholders 3.02%
% of Institutional Shareholders 6.66%

Financials:

Annual Sales, $ 32,180 K
Annual Net Income, $ -27,182 K

Growth:

1-Year Return 196.55%
3-Year Return 45.76%
5-Year Return -80.93%
5-Year Revenue Growth 102.60%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.02
Dividend Payout Ratio 0.00%

STX.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % N/A
Return-on-Assets % -39.02%
Profit Margin % -84.47%
Debt/Equity N/A
Price/Sales 2.52
Price/Book N/A
Book Value/Share -0.01
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.